Beta thalassaemia is an inherited blood condition that affects how the body produces a vital protein needed for healthy red blood cells. Treatment aims to manage symptoms, prevent complications, and maintain quality of life. The approach varies greatly depending on the severity of the condition, from no treatment at all for mild forms to lifelong blood transfusions and supportive therapies for severe cases. Medical science continues to explore new treatment paths, including advanced therapies that may one day change how we manage this condition.

How Treatment Helps People with Beta Thalassaemia

The main goal of treating beta thalassaemia is to ensure that the body has enough healthy red blood cells to carry oxygen throughout the body. Without sufficient oxygen delivery, people can feel exhausted, weak, and unable to perform daily activities. Treatment also focuses on preventing serious complications that can develop over time, such as damage to the heart, liver, and other organs^[1].

Treatment decisions depend heavily on which type of beta thalassaemia a person has. People with beta thalassaemia minor, also called trait, usually have such mild symptoms that they don’t need any medical intervention at all. Their bodies manage fairly well with slightly less hemoglobin than normal. On the other hand, people with beta thalassaemia major, the most severe form, require intensive lifelong treatment to survive. In between these extremes is beta thalassaemia intermedia, where people need treatment sometimes but not constantly^[2].

The treatment approach is highly individualized. Doctors consider the patient’s age, the severity of their anemia, the presence of other health conditions, and how well they respond to therapies. Children with severe forms need careful monitoring as they grow, because the condition can affect their development. Adults need ongoing management to prevent complications that accumulate over decades of living with the condition.

Medical societies around the world have developed guidelines to help doctors provide the best care. These recommendations are based on decades of research and clinical experience. At the same time, scientists are actively testing new therapies in clinical trials, searching for better ways to help people with beta thalassaemia live longer, healthier lives^[3].

Standard Treatment Approaches

Blood Transfusions

For people with moderate to severe beta thalassaemia, regular blood transfusions form the cornerstone of treatment. A blood transfusion is a procedure where healthy red blood cells from a donor are given through a tube inserted into a vein, usually in the arm. The transfusion typically takes place in a hospital and lasts several hours each time^[8].

People with beta thalassaemia major may need a blood transfusion approximately once a month throughout their lives. This is why doctors sometimes call this form “transfusion-dependent thalassaemia.” The frequency of transfusions depends on how quickly the body uses up or destroys the donated red blood cells. Some people with intermedia forms need transfusions only occasionally, perhaps when they have an infection or other illness that worsens their anemia^[9].

Blood transfusions are generally very safe procedures. However, they do carry risks. One of the most significant problems is that each transfusion delivers a large amount of iron to the body. Red blood cells are rich in iron, and over time, this iron accumulates in organs like the heart, liver, and hormone-producing glands. If left untreated, this iron overload can cause serious damage, leading to heart failure, liver disease, diabetes, and problems with growth and sexual development^[10].

Iron Chelation Therapy

Chelation therapy is treatment designed to remove excess iron from the body before it causes organ damage. This therapy is critically important for anyone receiving regular blood transfusions. The medicines used in chelation therapy are called chelating agents, which work by binding to iron in the blood and helping the body eliminate it^[10].

Three different chelating agents are currently approved for use. Desferrioxamine, often shortened to DFO, is given as an infusion. A small pump slowly feeds the liquid medicine through a needle inserted under the skin over eight to twelve hours. This is typically done five or six times each week. While effective, many people find this schedule burdensome because it requires wearing a pump overnight or during the day^[13].

Deferiprone, known as DFP, offers a more convenient alternative. It comes as a tablet or liquid taken by mouth three times daily. Sometimes doctors prescribe it alongside DFO to reduce the number of infusions needed. Deferiprone is particularly effective at removing iron from the heart muscle, making it especially valuable for people with significant cardiac iron buildup. However, it requires careful monitoring because it can occasionally cause low white blood cell counts, which increases infection risk^[13].

Deferasirox, or DFX, is the newest option. It’s taken once a day as a tablet that can be swallowed whole or dissolved in water or juice. This convenience makes it popular with many patients. Studies have shown it works as well as the older medicines at removing iron from the body and protecting the heart^[13].

Each chelation medicine has advantages and drawbacks. Your healthcare team will help determine which is most suitable based on how much iron has accumulated, which organs are most at risk, your daily routine, and how well you tolerate the medication. The key to successful chelation therapy is taking the medicine exactly as prescribed, even when you feel fine, because iron buildup causes damage silently over many years before symptoms appear.

Folic Acid Supplementation

Many doctors prescribe folic acid, a B vitamin, to people with beta thalassaemia. Folic acid helps the body develop red blood cells properly. When the body is working hard to make new red blood cells to compensate for anemia, it uses up folic acid more quickly than normal. Taking a folic acid supplement ensures the body has enough of this important nutrient^[8].

Folic acid supplementation is usually used alongside other treatments, not as a standalone therapy. It’s a simple, safe intervention that supports the body’s natural blood cell production processes.

Spleen Removal

The spleen is an organ that filters blood and removes old or damaged red blood cells. In people with beta thalassaemia, the spleen sometimes becomes overactive and destroys too many red blood cells, worsening anemia. The spleen can also grow very large, causing pain and discomfort in the abdomen^[5].

When these problems become severe, doctors may recommend surgical removal of the spleen, a procedure called splenectomy. Removing the spleen can reduce the number of blood transfusions needed and relieve abdominal discomfort. However, people without a spleen are at higher risk for certain infections, especially from bacteria. Therefore, before the surgery, patients receive special vaccinations, and they may need to take antibiotics long-term to prevent infections^[15].

Managing Complications

Beta thalassaemia and its treatments can lead to various complications that require additional management. Hormone problems are common, especially in people who have had iron overload. The excess iron can damage the glands that produce hormones controlling growth, sexual development, blood sugar, and thyroid function. Some patients need hormone replacement therapy to trigger puberty if it’s delayed, or medicines to manage diabetes or thyroid problems^[9].

Bone problems occur frequently. The body’s effort to produce more red blood cells causes the bone marrow to expand, which can weaken and deform bones, particularly in the face, skull, arms, and legs. Additionally, iron overload and some treatments can lead to osteoporosis, making bones brittle and prone to fractures. Doctors may prescribe medicines called bisphosphonates to strengthen bones, along with calcium and vitamin D supplements^[13].

Gallstones develop more often in people with beta thalassaemia because the breakdown of abnormal red blood cells produces substances that form stones in the gallbladder. If gallstones cause pain or infection, surgical removal of the gallbladder may be necessary.

Promising Treatments in Clinical Trials

Gene Therapy

Gene therapy represents one of the most exciting advances in beta thalassaemia treatment. Unlike traditional therapies that manage symptoms, gene therapy aims to correct the underlying genetic problem causing the disease. In January 2024, the U.S. Food and Drug Administration approved the first gene therapy for transfusion-dependent beta thalassaemia in patients 12 years and older. This therapy is called CASGEVY™, also known as exagamglogene autotemcel or exa-cel^[8].

The process works by taking a patient’s own blood stem cells and modifying them in a laboratory. Stem cells are special cells in the bone marrow that can develop into different types of blood cells. Scientists modify these stem cells so they can produce healthy hemoglobin. The modified cells are then returned to the patient as a one-time infusion^[8].

Before receiving the modified stem cells, patients must undergo high-dose chemotherapy. This powerful treatment removes the existing stem cells from the bone marrow, creating space for the modified cells to take hold and begin producing blood cells. The chemotherapy phase is intensive and requires hospitalization. Patients need to stay in the hospital for several weeks while their immune system recovers.

Gene therapy is a major undertaking and isn’t suitable for everyone. It requires specialized medical centers with expertise in this advanced treatment. Patients must be healthy enough to tolerate the chemotherapy phase. However, for those who can undergo it successfully, gene therapy offers the possibility of freedom from lifelong blood transfusions^[13].

Clinical trials continue to test other gene therapy approaches. Researchers are exploring different ways to modify stem cells and developing methods that might be safer or more effective. Some trials are testing gene therapies in younger patients or people with less severe forms of the disease.

Stem Cell Transplantation

Hematopoietic stem cell transplantation, also called bone marrow transplant, is currently the only established cure for beta thalassaemia. In this procedure, stem cells from a healthy donor replace the patient’s faulty stem cells. The donor’s cells can produce normal hemoglobin, potentially curing the disease^[10].

The transplant process is complex and carries significant risks. First, doctors must find a suitable donor whose cells closely match the patient’s tissue type. The best matches are usually siblings who share the same parents. Before the transplant, the patient receives chemotherapy or radiation to destroy their existing stem cells. Then the donor’s stem cells are infused into the patient’s bloodstream, where they travel to the bone marrow and, if successful, begin producing normal blood cells^[12].

The main risk is a condition called graft versus host disease, where the donor’s immune cells attack the patient’s body, seeing it as foreign. This can be life-threatening. Other risks include infections, bleeding, and organ damage from the preparatory chemotherapy. The procedure requires months of recovery, during which the immune system is severely weakened^[10].

Despite these risks, stem cell transplantation has successfully cured many people with beta thalassaemia major. The decision to proceed with a transplant involves carefully weighing the risks against the potential benefit of a cure. It’s most often considered for children and young adults who have a well-matched donor and are early in their disease course, before significant complications have developed.

Luspatercept

Luspatercept is a newer medication approved for adults with beta thalassaemia. It works differently from other treatments. Rather than replacing missing red blood cells with transfusions, luspatercept helps the body make its own red blood cells more effectively. It’s classified as an erythroid maturation agent, meaning it helps immature red blood cells develop into mature, functional cells that can carry oxygen^[13].

In beta thalassaemia, the bone marrow produces many immature red blood cells, but most of them die before they mature, a process called ineffective erythropoiesis. Luspatercept interferes with signals that cause these cells to die prematurely, allowing more of them to survive and mature into working red blood cells.

Luspatercept is given as an injection under the skin every three weeks. Clinical trials have shown that it can reduce the number of blood transfusions some patients need. It doesn’t work for everyone, and it doesn’t eliminate the need for transfusions entirely in most patients, but reducing transfusion frequency can significantly improve quality of life and decrease iron accumulation^[13].

Common side effects include bone pain, joint pain, dizziness, and headaches. Most side effects are mild to moderate. Luspatercept is currently approved for adults with beta thalassaemia who require regular transfusions. Research continues to determine if it might help younger patients or those with less severe disease.

Hydroxyurea

Hydroxyurea is a medication originally used to treat certain blood cancers. Researchers discovered it can also help some people with beta thalassaemia by stimulating the production of a different type of hemoglobin called fetal hemoglobin or hemoglobin F. Babies produce this type of hemoglobin before birth, but normally switch to adult hemoglobin after birth^[13].

In beta thalassaemia, the problem is with adult hemoglobin production. If the body can be coaxed into making more fetal hemoglobin, which doesn’t require beta-globin chains, it can partially compensate for the defective adult hemoglobin. This doesn’t cure the disease, but it can reduce anemia severity and decrease transfusion needs in some patients.

Hydroxyurea is taken as a daily pill. It doesn’t help everyone with beta thalassaemia; response varies considerably between individuals. Doctors may try it, particularly in people with beta thalassaemia intermedia, to see if it reduces symptoms and transfusion requirements. Side effects can include decreased white blood cell counts, which requires regular blood test monitoring.

Other Investigational Therapies

Scientists around the world are testing various novel approaches in clinical trials. Some experimental treatments focus on rebalancing the ratio of alpha-globin to beta-globin chains. In beta thalassaemia, there’s too much alpha-globin relative to beta-globin, and this imbalance contributes to red blood cell destruction. Therapies that reduce alpha-globin production might help restore balance^[11].

Other research explores ways to improve iron removal from the body or protect organs from iron damage using new chelation agents or antioxidants. Some clinical trials are testing combinations of existing treatments to see if they work better together than individually.

Clinical trials for beta thalassaemia are conducted in phases. Phase I trials test a new treatment in a small number of people primarily to evaluate safety and determine appropriate dosing. Phase II trials involve more patients and focus on whether the treatment actually works to improve the condition. Phase III trials are large studies comparing the new treatment against current standard treatments to see if it’s better, as good, or worse.

Many clinical trials are conducted in multiple countries, including the United States, Europe, and parts of Asia where beta thalassaemia is more common. Eligibility to participate depends on factors like age, disease severity, previous treatments received, and overall health status. Information about active clinical trials can be found through hospital thalassaemia centers and patient advocacy organizations.

Most common treatment methods

• Blood transfusions
  • Regular transfusions of healthy red blood cells to treat anemia in moderate to severe cases
  • Typically needed monthly for beta thalassaemia major
  • Procedure takes several hours in a hospital setting
  • Reduces symptoms like fatigue, weakness, and shortness of breath
• Iron chelation therapy
  • Desferrioxamine (DFO) given as infusion five to six times weekly over 8-12 hours
  • Deferiprone (DFP) taken as tablet or liquid three times daily
  • Deferasirox (DFX) taken once daily as tablet
  • Essential for preventing organ damage from iron overload
  • Deferiprone particularly effective for removing cardiac iron
• Folic acid supplementation
  • B vitamin supplement to support red blood cell development
  • Used alongside other treatments
• Surgical interventions
  • Splenectomy (spleen removal) when the spleen becomes enlarged or overactive
  • Gallbladder removal if gallstones cause pain or infection
• Gene therapy
  • CASGEVY™ (exagamglogene autotemcel) approved for transfusion-dependent beta thalassaemia in patients 12 years and older
  • One-time treatment using patient’s own modified stem cells
  • Requires high-dose chemotherapy preparation
  • Aims to enable production of healthy hemoglobin
• Stem cell transplantation
  • Bone marrow transplant from matched donor
  • Currently the only established cure
  • Involves preparatory chemotherapy or radiation
  • Carries risks including graft versus host disease and infection
• Erythroid maturation agents
  • Luspatercept injection given every three weeks
  • Helps immature red blood cells develop properly
  • Can reduce transfusion frequency in some adults
• Hydroxyurea
  • Daily oral medication that stimulates fetal hemoglobin production
  • May reduce transfusion needs in some patients with intermedia forms
• Supportive medications
  • Bisphosphonates to strengthen bones and prevent osteoporosis
  • Hormone replacement therapy for hormone deficiencies
  • Vaccinations and antibiotics to prevent infections
  • Thyroid hormone medication for thyroid problems